Skip to content
Search

Latest Stories

J&J and WHO extend worldwide support for smoking cessation

On ‘World No Tobacco Day’ (May 31), Johnson & Johnson Consumer Health and the WHO under the Access Initiative for Quitting Tobacco marked the first anniversary of their partnership supporting countries in facilitating the improvement of public health through smoking cessation.​

In partnership with the World Health Organisation, Johnson & Johnson’s Nicorette brand is supporting communities with some of the highest rates of tobacco use in the world.


While 60 per cent of the 1.3 billion tobacco users globally have expressed a desire to quit, only 30 per cent have access to the support and tools necessary to help them to do so successfully.

Since the Covid-19 pandemic began, nearly one-third of smokers in the UK report smoking more-a habit linked to increased risk of severe illness.

To-date, J&J has donated $800,000 or £56, 3640 of NRT products to Jordan- where smoking contributes to 80 per cent of premature deaths.

The funds used to support thousands of front-line workers and patients with non-communicable diseases to quit smoking during the Covid-19 pandemic and beyond.

“The donation of nicotine replacement therapy (NRT) has enabled the Ministry of Health in Jordan to scale its comprehensive smoking cessation services, providing over 5,400 people with nicotine patches combined with personal counselling and digital support,” Johnson & Johnson said in an update on it efforts to support smokers to quit their habbit.

William Twomey, senior director Smoking Cessation Franchise, Johnson & Johnson Consumer Health said: “It is with the commitment and support of partners, government and other stakeholders, that we are able to work toward creating greater equity and access to NRTs in the more than 65 countries currently being served by Nicorette.”

“At Johnson & Johnson Consumer Health, we recognize that communities around the world need support to address this public health crisis, which has been exacerbated by Covid-19. This unmet need is a major driver behind the partnership with the WHO to reduce tobacco-related harm with smoking cessation initiatives and expanded access to NRTs where they are needed most.”

Vinayak Prasad, head of the No Tobacco Unit at the WHO said: "Studies show that nicotine replacement therapies like gums and patches can double your chances of quitting. The WHO welcomed the partnership with Johnson & Johnson Consumer Health to help get gums and patches into the hands of people wanting to quit to lower their risk of severe Covid-19.”

More For You

Technology and transformation: How pharmacies are innovating to survive and thrive

L-R: Yasmin Karsan, Pritee Panchmatia, and Fin McCaul

Adopt, Adapt, Advance: Pharmacists share the impact of embracing technology

With mounting financial pressures and rising patient demand, it has become more important than ever for pharmacies to embrace smarter, more efficient ways of working.

At the recent Pharmacy Business Conference, industry leaders came together to discuss the benefits of adopting new technologies, if implemented correctly.

Keep ReadingShow less
How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less